Takeda Announces 149th Annual General Meeting of Shareholders

An update from Takeda Pharmaceutical Company ( (TAK) ) is now available.

Takeda Pharmaceutical Company Limited has announced the convocation of its 149th Annual General Meeting of Shareholders, scheduled for June 25, 2025, at the Imperial Hotel in Osaka. The meeting will cover reports on the business and financial statements for the fiscal year ending March 31, 2025, and will include resolutions on the appropriation of surplus, election of directors, and payment of bonuses to directors. Shareholders are encouraged to exercise their voting rights electronically or by mail before June 24, 2025. The meeting will be streamed live online, allowing remote participation, reflecting Takeda’s commitment to shareholder engagement and transparency.

The most recent analyst rating on (TAK) stock is a Hold with a $13.40 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Company stock, see the TAK Stock Forecast page.

Spark’s Take on TAK Stock

According to Spark, TipRanks’ AI Analyst, TAK is a Outperform.

Takeda Pharmaceutical Company demonstrates strong financial performance, driven by consistent revenue and profit growth, a solid balance sheet, and effective cash flow management. While the company’s technical indicators show moderate bullish momentum, the high P/E ratio raises valuation concerns. The mixed earnings call highlights both promising product launches and challenges from generic competition. Overall, Takeda’s strong fundamentals and promising pipeline are somewhat tempered by valuation and competitive pressures, resulting in an overall stock score of 71.

To see Spark’s full report on TAK stock, click here.

More about Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Tokyo, Japan. It operates in the healthcare industry, focusing on the development and production of pharmaceutical products, with a strong emphasis on research and development in areas such as oncology, gastroenterology, and neuroscience.

Average Trading Volume: 2,140,681

Technical Sentiment Signal: Buy

Current Market Cap: $46.12B

See more data about TAK stock on TipRanks’ Stock Analysis page.